Anika Q2 revenue $32.6M (+16% YoY); raises FY 2026 guidance, adj. EBITDA margin 13-17%

Anika Therapeutics, Inc.

Q2 revenue $32.6M, up 16% YoY; Commercial Channel record $13.9M (+17%); OEM $18.7M (+14%).
Gross margin 65%; net income $3.3M ($0.24 diluted EPS); adjusted EBITDA $7.1M (22% margin).
Raising FY 2026 guidance: total revenue growth 5-10% (prev 1-9%); adj. EBITDA margin 13-17% (prev 5-10%).
Revised 2027 Commercial revenue growth 5-15% (prev 10-20%); total company flat to 5% growth.
International revenue record $12.6M (+22% YoY); Integrity units up 39% YTD; Hyalofast/Cingal progress.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.